These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

653 related items for PubMed ID: 18182599

  • 21. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
    Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, Halperin SA, Langley JM, McNeil SA, Pollard AJ.
    Vaccine; 2012 Apr 16; 30(18):2831-8. PubMed ID: 22394992
    [Abstract] [Full Text] [Related]

  • 22. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
    Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P.
    Clin Vaccine Immunol; 2011 Mar 16; 18(3):483-6. PubMed ID: 21177912
    [Abstract] [Full Text] [Related]

  • 23. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
    Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Graña MG, Heijnen E, Smolenov I, Dull PM.
    Hum Vaccin Immunother; 2015 Mar 16; 11(6):1507-17. PubMed ID: 25969894
    [Abstract] [Full Text] [Related]

  • 24. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
    Read RC, Dull P, Bai X, Nolan K, Findlow J, Bazaz R, Kleinschmidt A, McCarthy M, Wang H, Toneatto D, Borrow R.
    Vaccine; 2017 Jan 11; 35(3):427-434. PubMed ID: 27912986
    [Abstract] [Full Text] [Related]

  • 25. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
    Lee HJ, Chung MH, Kim WJ, Hong YJ, Choi KM, Lee J, Oh CE, Welsch JA, Kim KH, Hong KB, Dagnew AF, Bock H, Dull PM, Odrljin T.
    Int J Infect Dis; 2014 Nov 11; 28():204-10. PubMed ID: 25316331
    [Abstract] [Full Text] [Related]

  • 26. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M.
    BMC Infect Dis; 2015 Oct 06; 15():409. PubMed ID: 26437712
    [Abstract] [Full Text] [Related]

  • 27. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
    Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM.
    Clin Vaccine Immunol; 2009 Dec 06; 16(12):1810-5. PubMed ID: 19812260
    [Abstract] [Full Text] [Related]

  • 28. Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.
    Blanchard-Rohner G, Snape MD, Kelly DF, O'Connor D, John T, Kibwana E, Parks H, Ford K, Dull PM, Pollard AJ.
    Pediatr Infect Dis J; 2013 Jul 06; 32(7):768-76. PubMed ID: 23538521
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T, Booy R, Marshall HS, Richmond P, Nissen M, Ziegler JB, Baine Y, Traskine M, Jastorff A, Van der Wielen M.
    Pediatr Infect Dis J; 2019 Jun 06; 38(6):643-650. PubMed ID: 31116180
    [Abstract] [Full Text] [Related]

  • 30. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
    Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM.
    Hum Vaccin Immunother; 2012 Dec 01; 8(12):1892-903. PubMed ID: 23032159
    [Abstract] [Full Text] [Related]

  • 31. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
    Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P.
    Pediatr Infect Dis J; 2012 Jan 01; 31(1):64-71. PubMed ID: 22094635
    [Abstract] [Full Text] [Related]

  • 32. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
    Lalwani S, Agarkhedkar S, Gogtay N, Palkar S, Agarkhedkar S, Thatte U, Vakil H, Jonnalagedda R, Pedotti P, Hoyle M, Bhusal C, Arora A.
    Int J Infect Dis; 2015 Sep 01; 38():36-42. PubMed ID: 26166699
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
    Beran J, Dražan D, Enweonye I, Bhusal C, Toneatto D.
    mSphere; 2021 Dec 22; 6(6):e0055321. PubMed ID: 34787449
    [Abstract] [Full Text] [Related]

  • 34. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
    Alberer M, Burchard G, Jelinek T, Reisinger EC, Meyer S, Forleo-Neto E, Dagnew AF, Arora AK.
    J Travel Med; 2015 Dec 22; 22(2):105-14. PubMed ID: 25483566
    [Abstract] [Full Text] [Related]

  • 35. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G, Van der Wielen M, Reda M, Medlej F, Tabet C, Boutriau D, Sumbul A, Anis S, Miller JM.
    Int J Infect Dis; 2012 Aug 22; 16(8):e608-15. PubMed ID: 22704725
    [Abstract] [Full Text] [Related]

  • 36. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants.
    Rennels M, King J, Ryall R, Papa T, Froeschle J.
    Pediatr Infect Dis J; 2004 May 22; 23(5):429-35. PubMed ID: 15131466
    [Abstract] [Full Text] [Related]

  • 37. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A, Silas PE, Lamas MR, Aragón CF, Chiu NC, Chiu CH, Acuña TH, Castrejón Tde L, Izu A, Odrljin T, Smolenov I, Hohenboken M, Dull PM.
    Vaccine; 2014 Feb 12; 32(8):965-72. PubMed ID: 24397906
    [Abstract] [Full Text] [Related]

  • 38. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N.
    Drugs Aging; 2013 May 12; 30(5):309-19. PubMed ID: 23494214
    [Abstract] [Full Text] [Related]

  • 39. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
    Tipton M, Daly W, Senders S, Block SL, Lattanzi M, Mzolo T, Barbi S, Pellegrini M, Keshavan P.
    Vaccine; 2019 Sep 30; 37(42):6171-6179. PubMed ID: 31495595
    [Abstract] [Full Text] [Related]

  • 40. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
    Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, Miller J.
    Eur J Pediatr; 2013 May 30; 172(5):601-12. PubMed ID: 23307281
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.